Phrixus Pharmaceuticals

Phrixus Pharmaceuticals

Phrixus Pharmaceuticals

Phrixus Pharmaceuticals is developing Carmeseal™ (poloxamer 188 or P188) for Duchenne muscular dystrophy and acute decompensated heart failure.
Founded
2006
Follow us
Alexa global traffic share
Twitter followers
Latest funding
Undisclosed amount
Venture capital - 2007
Team Size
2
Employees

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when Phrixus Pharmaceuticals makes some noise.